Short acting beta agonist inhalers by all Sub-ICB Locations

Why it matters: Why Asthma Still Kills reports that high use of short acting beta agonists (salbutamol and terbutaline) and poor adherence to inhaled corticosteroids in asthma suggests poor control - these patients should be reviewed regularly to ensure good control.

The NHS England National Medicines Optimisation Opportunities for 2023/24 identify improving patient outcomes from the use of inhalers as an area for improvement.

Description: Prescribing of short acting beta agonist (SABA) inhalers - salbutamol and terbutaline - compared with prescribing of inhaled corticosteroid inhalers and SABA inhalers


Tagged as: Standard, Respiratory, National medicines optimisation opportunities, Safety (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.